# A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

> **NCT03044249** · PHASE2 · TERMINATED · sponsor: **Mediti Pharma Inc.** · enrollment: 81 (actual)

## Conditions studied

- Psychosis
- Dementia
- Aggression
- Agitation
- Alzheimer Dementia

## Interventions

- **DRUG:** MP-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03044249
- **Lead sponsor:** Mediti Pharma Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-04
- **Primary completion:** 2020-01-30
- **Final completion:** 2020-01-30
- **Target enrollment:** 81 (ACTUAL)
- **Why stopped:** Statistical futility; totality of evidence suggests study unlikely to meet endpoint
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03044249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03044249, "A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03044249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*